Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 484.5 Million EUR | -51.32% |
| 2022 | 995.2 Million EUR | 15.0% |
| 2021 | 865.42 Million EUR | 83.43% |
| 2020 | 471.8 Million EUR | 42.1% |
| 2019 | 332.02 Million EUR | 10.59% |
| 2018 | 300.23 Million EUR | 35.42% |
| 2017 | 221.7 Million EUR | -1.87% |
| 2016 | 225.91 Million EUR | 22.43% |
| 2015 | 184.53 Million EUR | 53.3% |
| 2014 | 120.37 Million EUR | 18.77% |
| 2013 | 101.34 Million EUR | 16.22% |
| 2012 | 87.2 Million EUR | 22.55% |
| 2011 | 71.15 Million EUR | 18.8% |
| 2010 | 59.89 Million EUR | 23.21% |
| 2009 | 48.61 Million EUR | 44.12% |
| 2008 | 33.73 Million EUR | 142.45% |
| 2007 | 13.91 Million EUR | -94.33% |
| 2006 | 245.24 Million EUR | 10.7% |
| 2005 | 221.52 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 112.8 Million EUR | -0.35% |
| 2024 Q1 | 113.2 Million EUR | 148.25% |
| 2024 Q3 | 70.8 Million EUR | -37.23% |
| 2023 Q4 | 45.6 Million EUR | -40.7% |
| 2023 Q3 | 76.9 Million EUR | -58.59% |
| 2023 Q2 | 185.7 Million EUR | 9.88% |
| 2023 Q1 | 169 Million EUR | -21.83% |
| 2023 FY | 484.5 Million EUR | -51.32% |
| 2022 FY | 995.2 Million EUR | 15.0% |
| 2022 Q4 | 216.2 Million EUR | -25.32% |
| 2022 Q1 | 348.8 Million EUR | 14743.16% |
| 2022 Q3 | 289.5 Million EUR | -1.7% |
| 2022 Q2 | 294.5 Million EUR | -15.57% |
| 2021 Q1 | 206.2 Million EUR | 64.11% |
| 2021 Q2 | 219.8 Million EUR | 6.6% |
| 2021 Q3 | 233.7 Million EUR | 6.32% |
| 2021 Q4 | -2.38 Million EUR | -101.02% |
| 2021 FY | 865.42 Million EUR | 83.43% |
| 2020 Q4 | 125.64 Million EUR | -16.4% |
| 2020 Q3 | 150.3 Million EUR | 40.34% |
| 2020 Q2 | 107.1 Million EUR | -0.37% |
| 2020 Q1 | 107.5 Million EUR | 64.34% |
| 2020 FY | 471.8 Million EUR | 42.1% |
| 2019 Q3 | 85.6 Million EUR | -4.04% |
| 2019 Q4 | 65.41 Million EUR | -23.58% |
| 2019 FY | 332.02 Million EUR | 10.59% |
| 2019 Q2 | 89.2 Million EUR | 11.36% |
| 2019 Q1 | 80.1 Million EUR | -2.13% |
| 2018 Q2 | 72.1 Million EUR | 25.17% |
| 2018 Q1 | 57.6 Million EUR | 10.28% |
| 2018 FY | 300.23 Million EUR | 35.42% |
| 2018 Q4 | 81.84 Million EUR | 9.27% |
| 2018 Q3 | 74.9 Million EUR | 3.88% |
| 2017 Q2 | 57.9 Million EUR | 0.17% |
| 2017 FY | 221.7 Million EUR | -1.87% |
| 2017 Q4 | 52.23 Million EUR | -6.06% |
| 2017 Q3 | 55.6 Million EUR | -3.97% |
| 2017 Q1 | 57.8 Million EUR | -14.4% |
| 2016 Q1 | 50.8 Million EUR | -5.38% |
| 2016 Q4 | 67.52 Million EUR | 7.0% |
| 2016 FY | 225.91 Million EUR | 22.43% |
| 2016 Q3 | 63.1 Million EUR | 6.05% |
| 2016 Q2 | 59.5 Million EUR | 17.13% |
| 2015 Q4 | 53.68 Million EUR | -4.47% |
| 2015 Q1 | 41.3 Million EUR | 14.5% |
| 2015 Q2 | 45.9 Million EUR | 11.14% |
| 2015 FY | 184.53 Million EUR | 53.3% |
| 2015 Q3 | 56.2 Million EUR | 22.44% |
| 2014 Q4 | 36.07 Million EUR | 19.05% |
| 2014 Q2 | 30.5 Million EUR | 24.49% |
| 2014 Q3 | 30.3 Million EUR | -0.66% |
| 2014 FY | 120.37 Million EUR | 18.77% |
| 2014 Q1 | 24.5 Million EUR | -15.39% |
| 2013 Q2 | 30.6 Million EUR | 0.0% |
| 2013 Q4 | 28.95 Million EUR | 24.82% |
| 2013 Q3 | 23.2 Million EUR | -24.18% |
| 2013 FY | 101.34 Million EUR | 16.22% |
| 2012 FY | 87.2 Million EUR | 22.55% |
| 2012 Q2 | 21.3 Million EUR | 0.0% |
| 2011 Q2 | 15.4 Million EUR | 0.0% |
| 2011 FY | 71.15 Million EUR | 18.8% |
| 2010 FY | 59.89 Million EUR | 23.21% |
| 2010 Q2 | 14.8 Million EUR | 0.0% |
| 2009 FY | 48.61 Million EUR | 44.12% |
| 2008 FY | 33.73 Million EUR | 142.45% |
| 2007 FY | 13.91 Million EUR | -94.33% |
| 2006 FY | 245.24 Million EUR | 10.7% |
| 2005 FY | 221.52 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | -41515.846% |
| Ansell Limited | 129.3 Million USD | -274.71% |
| Ansell Limited | 129.3 Million USD | -274.71% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 31.13 Million USD | -1455.967% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.59 Million USD | 30462.831% |
| Psykey, Inc. | -797.5 Thousand USD | 60852.046% |
| ConvaTec Group Plc | 262.7 Million USD | -84.431% |
| ConvaTec Group Plc | 262.7 Million USD | -84.431% |
| Encision Inc. | -640.78 Thousand USD | 75710.62% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 341754.326% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 440835.013% |
| Innovative MedTech Inc. | -4.27 Million USD | 11435.783% |
| LifePoint, Inc. | -7.49 Million USD | 6564.113% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 7576.852% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | -146718.182% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -122.89 Thousand USD | 394355.025% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | 103785.6% |
| SmileDirectClub, Inc. | -241.15 Million USD | 300.907% |
| Sector 10, Inc. | -39.84 Thousand USD | 1216092.37% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | -51.593% |
| SheerVision, Inc. | 155.72 Thousand USD | -311023.383% |
| United Health Products, Inc. | -2.42 Million USD | 20066.71% |
| Vasamed, Inc. | 4.74 Million USD | -10116.557% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 21219.016% |
| Yubo International Biotech Limited | -1.2 Million USD | 40300.029% |